Digitisation | April 01, 2022
Arzeda closes US$33 million Series B funding
Arzeda harnesses the power of computer-designed enzymes and applies the latest advances in digital biology
Arzeda harnesses the power of computer-designed enzymes and applies the latest advances in digital biology
A major unresolved question in the field, however, is how do this machinery rapidly searches for and finds rare stretches of damage amid the "vast fields" of undamaged DNA
Meteoric Biopharmaceuticals have made rapid strides in the development of enzymes, probiotics and veterinary health products. It is seeking opportunities to scale up its growth backed by cutting edge R&D. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals spoke to Thomas C Thottathil on the way forward
The accelerated growth of Medix Biochemica will establish its status as the ultimate IVD raw materials supplier
Sevelamer Hydrochloride tablets, 800 mg is a generic equivalent of Renagel tablets, 800 mg
Dr. Raman has succeeded Victoria Richon
Sanofi unveiled a new bold and unifying corporate brand that supports the modernization and transformation the company launched in December 2019
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
Subscribe To Our Newsletter & Stay Updated
